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Cisplatin is a highly effective chemotherapeutic agent. However, its use is limited by
nephrotoxicity. Enalapril is an angiotensin I-converting enzyme inhibitor used for the
treatment of hypertension, mainly through the reduction of angiotensin II formation,
but also through the increase of kinins half-life. Kinin B1 receptor is associated
with inflammation and migration of immune cells into the injured tissue. We have
previously shown that the deletion or blockage of kinin B1 and B2 receptors can
attenuate cisplatin nephrotoxicity. In this study, we tested enalapril treatment as a tool
to prevent cisplatin nephrotoxicity. Male C57Bl/6 mice were divided into 3 groups:
control group; cisplatin (20 mg/kg i.p) group; and enalapril (1.5mg;kg i.p) + cisplatin
group. The animals were treated with a single dose of cisplatin and euthanized after
96 h. Enalapril was able to attenuate cisplatin-induced increase in creatinine and urea,
and to reduce tubular injury and upregulation of apoptosis-related genes, as well
as inflammatory cytokines in circulation and kidney. The upregulation of B1 receptor
was blocked in enalapril + cisplatin group. Carboxypeptidase M expression, which
generates B1 receptor agonists, is blunted by cisplatin + enalapril treatment. The
activity of aminopeptidase P, a secondary key enzyme able to degrade kinins, is
restored by enalapril treatment. These findings were confirmed in mouse renal epithelial
tubular cells, in which enalaprilat (5µM) was capable of decreasing tubular injury and
inflammatory markers. We treated mouse renal epithelial tubular cells with cisplatin
(100µM), cisplatin+enalaprilat and cisplatin+enalaprilat+apstatin (10µM). The results
showed that cisplatin alone decreases cell viability, cisplatin plus enalaprilat is able to
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restore cell viability, and cisplatin plus enalaprilat and apstatin decreases cell viability.
In the present study, we demonstrated that enalapril prevents cisplatin nephrotoxicity
mainly by preventing the upregulation of B1 receptor and carboxypeptidase M and the
increased concentrations of kinin peptides through aminopeptidase activity restoration.
Keywords: cisplatin nephrotoxicity, kinins, aminopeptidase P, inflammation, enalapril
INTRODUCTION
Cisplatin is an effective antitumor agent often used in
chemotherapy to treat multiple types of tumor. However,
cisplatin nephrotoxicity is a limiting factor for its use (Arany and
Safirstein, 2003; Miller et al., 2010). In order to protect the kidney
against injury, it is necessary to understand the relationship
between renal injury and several signaling pathways, and how
this results in necrosis and apoptosis of renal tubular cells. It is
well-described that during cisplatin treatment, immune cells and
pro-inflammatory cytokines are increased in the kidney (Okusa,
2002; Ramesh and Reeves, 2002, 2003; Miller et al., 2010).
Enalapril is a highly effective angiotensin-converting enzyme
(ACE) inhibitor and is widely used as an antihypertensive drug.
It acts not only by preventing the formation of angiotensin II
(AngII), which is the main effector vasoconstrictor peptide of
the renin-angiotensin system (RAS), but also by avoiding the
degradation of vasodilator peptides of the kallikrein-kinin system
(KKS) (Marcic and Erdös, 2000; Souza Dos Santos et al., 2001).
The main effect of enalapril in the control of hypertension is
related to the inhibition of AngII formation. This peptide has
shown to be able to activate inflammatory genes regulated by
NF-κB, both in vivo and in vitro (Passos-Silva et al., 2015).
Kinins are well-known for their ability to affect immune
response. Our group has already shown the role of both kinin
receptors in cisplatin-induced acute kidney injury, where the
deletion or blockage of kinin B1 and B2 receptors attenuates
the nephrotoxicity caused by cisplatin exposure (Estrela et al.,
2014a,b). Studies have revealed that ACE influences the
regulation of both kinin receptors in vascular smooth muscle
cells (Ignjacev-Lazich et al., 2005). Moreover, it has already been
shown that ACE inhibition protects against some types of renal
disease (Ghosh et al., 2009, 2012; Vejakama et al., 2012; Ding
et al., 2014; Ham et al., 2018; Panico et al., 2019), including
cisplatin-induced kidney disfunction (El-Sayed el et al., 2008),
but only renal function and reactive oxygen species were assessed
in this work. Given that (a) inflammation has an important
role in cisplatin nephrotoxicity; (b) AngII influences the
regulation of inflammation-related genes; and (c) ACE inhibition
reduces kinin degradation, we decided to verify whether the
protective effect of ACE inhibition on the attenuation of cisplatin
nephrotoxicity is related to KKS regulation.
MATERIALS AND METHODS
Animals
Male C57BL/6 mice weighing 25–30 g and aged 12–14 weeks
were used for these experiments. The animals were obtained
from the Animal Care Facility of the Federal University of
São Paulo (UNIFESP). All animals were housed in individual,
standard cages and had free access to water and food. All
procedures were previously reviewed and approved by the
internal ethical committee of the Federal University of São Paulo
(CEUA 155783).
Experimental Protocol
The mice were divided into 3 groups for each experiment:
control group, cisplatin (CIS)-treated group and cisplatin plus
enalapril (ENAL+CIS)-treated group. We used n = 5–6 for each
experiment and condition.
Drug Treatment
Single doses of Cisplatin (Ramesh and Reeves, 2002, 2003;
Estrela et al., 2014b, 2017a,b) (20 mg/kg—Bergamo, Taboão da
Serra, Brazil) were injected intraperitoneally. Tissues and blood
were collected 4 days after injection. Enalapril (1.5 mg/kg i.p)
< (Cozzoli et al., 2011; Jackson et al., 2013; Fendrich et al.,
2014) > was dissolved in PBS and the treatment started 1 day
prior to cisplatin administration and was given daily until tissue
collection. Control animals received PBS intraperitoneally at
same volume as cisplatin.
Blood Sampling and Tissue Collection
The mice were anesthetized with ketamin (91 mg/kg) and xylazin
(9.1 mg/kg) intraperitoneally, and blood was collected via heart
puncture. Blood was allowed to clot for 2 h at room temperature
and then centrifuged for 20min at 2,000 x g. The samples were
then stored at −20◦C. Kidney tissue was collected and renal
capsule was removed. Transversal cuts were performed and the
kidneys were immediately frozen in nitrogen and then stored
at−80◦C.
Renal Function
Serum creatinine and urea levels were used to determine renal
function. Samples were analyzed using commercially available
colorimetric assay (Pereira et al., 2011; Estrela et al., 2014a,b,
2017a) kits (Labtest, Lagoa Santa, Brazil).
Quantification of Gene Expression
Kidney samples were frozen at −80◦C immediately after
collection. Total RNA was isolated using TRIzol Reagent
(Invitrogen, Carlsbad, CA). The RNA integrity was assessed by
electrophoresis on an agarose gel. cDNA was synthesized using
the “High Capacity cDNA Reverse Transcription Kit” (Applied
Biosystems). Standard curves were plotted to determine the
amplification efficiency for each primer pair. Real-time PCR
was performed using two systems: the TaqMan system (Applied
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Biosystems, Carlsbad, CA) using probes for IL-6 (mm00446190-
m1), TNF-α (mm00443258-m1), B1R (mm00432059-s1), B2R
(mm00437788-s1) and GAPDH (mm99999915-g1); and the
SYBR Green system (Thermo Scientific, Waltham, MA) using
specific primers for β-actin, IL-1β, NGAL, Bax, Bcl-2, Tnfr-2,
Ace, AT1R, AT2R, and CPM; the primers were designed using
primer3 web and their specificity was confirmed using NCBI
primer-BLAST; their sequences are shown inTable 1. The cycling
conditions for both TaqMan and SYBR Green reactions were as
follows: 10min at 95◦C, followed by 45 cycles of 30 s at 95◦C,
30 s at 60◦C, and 30 s at 72◦C. Target mRNA expression was
normalized to β-actin for SYBR and to GAPDH for TaqMan,
and expressed as a relative value using the comparative threshold
cycle (Ct) method (2–11Ct) (Livak and Schmittgen, 2001). The
expression levels of the genes of interest were normalized to the
control group and presented as fold change.
Histological Analyses
Formaldehyde-fixed paraffin sections of kidneys were stained
with hematoxylin and eosin (H&E). Optic light microscopy was
employed to analyze the samples. Images were acquired at ×40
magnification. Epithelial desquamation, cellular debris, epithelial
flattening, presence of cylinders, and dilation of the tubular
lumen were used as criteria for tubular injury. The injuries were
graded using a scoring procedure, in which grade 1 = 0–5% of
the total kidney area was compromised; grade 2 = 6–10%; grade
3= 11–25%; grade 4= 26–50%, and grade 5≥ 50% (Estrela et al.,
2014a,b, 2017a; Barrera-Chimal et al., 2017). Histological analysis
was performed blind to experimental groups.
TABLE 1 | Sequences of primers used in real-time PCR assays.
Gene Primers
β-actin 5′-CTGGCCTCACTGTCCACCTT-3′
5′-CGGACTCATCGTACTCCTGCTT-3′
IL-1β 5′-AGGAGAACCAAGCAACGACA-3′
5′-CGTTTTTCCATCTTCTTCTTTG-3′
BAX 5′-CGGCGAATTGGAGATGAACTG-3′
5′-GCAAAGTAGAAGAGGGCAACC-3′
BCL-2 5′-ACCGTCGTGACTTCGCAGAG-3′
5′-GGTGTGCAGATGCCGGTTCA-3′
TNFR-2 5′-GTCGCGCTGGTCTTCGAACTG-3′
5′-GGTATACATGCTTGCCTCACAGTC-3′
ACE 5′-CTCAGCCTGGGACTTCTACAAC-3′
5′-CTCCATGTTCACAGAGGTACACT-3′
AT1R 5′-CCATTGTCCACCCGATGAAG-3′
5′-TGCAGGTGACTTTGGCCAC-3′
AT2R 5′-CAGCAGCCGTCCTTTTGATAA-3′
5′-TTATCTGATGGTTTGTGTGAGCAA-3′
NGAL 5′-ATGTGCAAGTGGCCACCACG-3′
5′-CGCATCCCAGTCAGCCACAC-3′
IL-1β, interleukin 1β; BAX, Bcl-2-associated X; BCL-2, B-cell lymphoma 2; TNFR-2,
tumor necrosis factor receptor 2; ACE, angiotensin converting enzyme; AT1R, angiotensin
II receptor type I; AT2R, angiotensin II receptor type II. NGAL, neutrophil gelatinase-
associated lipocalin.
Enzyme-Linked Immunosorbent Assay
Serum samples were frozen and stored at −20◦C immediately
after collection. Serum levels of TNF-α (MTA00B), IL-1β
(MLB00C) and IL-6 (M6000B) were quantified using Quantikine
ELISA mouse kits specific for each cytokine (R&D Systems,
Minneapolis, MN), according to the manufacturer’s instructions.
Aminopeptidase P Activity
The assessment was performed by fluorescence measurement
(λex = 340 nm and λem = 410 nm) followed by hydrolysis of
specific substrate Lys(Abz)-Pro-Pro-pNA (Bachem). Briefly, an
aliquot of homogenized tissue or mouse serum was incubated
with buffer (0.1M Tris-HCl, 0.5mMMnCl2, pH 8.0) and 20µM
of Lys(Abz)-Pro-Pro-pNA substrate at 37◦C, under stirring,
for 20min (Abid et al., 2009). The fluorescence was detected
and analyzed by spectrofluorometer (SpectraMax Gemini XS,
Molecular Devices). The fluorescence parameter was set as
arbitrary fluorescence units. Apstatin was used as inhibitor for
Aminopeptidase P activity at 10 µM.
Cell Treatments
Mouse epithelial tubular cells MM55.K (ATCC) were cultured
in Dulbecco’s modified Eagle’s medium high (DMEM high;
ThermoFisher), 10% fetal bovine serum (FBS; Dutcher), and
1% Penicillin Streptomycin (P/S; ThermoFisher). The cells were
incubated at 37◦C with 5% CO2. At 90% confluence, they were
exposed to 0.05% trypsin-EDTA (ThermoFisher) and seeded in 6-
well plates with 0.1 × 106 cells per well for qPCR and 96-well
plates with 2,000 cells per well for MTT assay. The cells were
incubated for 24 h with Enalaprilat (5µM, Sigma) or Apstatin
(10µM, Enzo Life Science), both diluted in H2O and thereafter
treated or not for 24 h with cis-Diammineplatinum(II) dichloride
(50 or 100µM, Sigma), diluted in 0.9% NaCl solution.
Cell Viability Assay
After treatments, cell viability was measured with a cell
proliferation kit (MTT, Sigma) according to the manufacturer’s
instructions. Briefly, MTT labeling reagent was added to the
cell culture media for 4 h at 37◦C, and then the solubilization
solution was added overnight at 37◦C. The absorbance values
were obtained at 550 nm with Infinite 200 Pro (Tecan).
Statistical Analysis
All data is presented as mean ± s.e.m. Intergroup differences
significance was assessed by one-way analysis of variance
(ANOVA) with the Tukey correction for multiple comparisons.
The value for statistical significance was established at P<0.05.
All statistical analyses were performed using GraphPad Prism 5
(GraphPad, La Jolla, CA).
RESULTS
Enalapril Reduces Cisplatin-Induced
Renal Injury
We injected enalapril (1.5 mg/kg i.p) as a preventive treatment
in mice treated with cisplatin (20 mg/kg i.p). All animals
treated with cisplatin presented weight loss, but enalapril was
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able to attenuate this effect (Figure 1A). We measured renal
function markers and enalapril-treated mice presented lower
creatinine and urea serum levels (Figures 1B,C). Moreover,
enalapril-treated mice (ENAL+CIS group) showed lower tubular
injury scores as analyzed by histology, presenting less epithelial
desquamation, cellular debris, epithelial flattening, presence of
cylinders, and dilation of the tubular lumen than animals treated
with cisplatin alone (CIS group) (Figures 1D–G).
Inflammatory Cytokines and Apoptosis
Markers Were Reduced by Enalapril
Treatment
Serum levels of some pro-inflammatory factors and markers,
such as IL-1β, TNF-α, and IL-6 were measured. A reduction
mainly in TNF levels was observed in the ENAL+CIS group
when compared to the CIS group (Figures 2A–C). We also
analyzed the renal expression of these factors and all of them
presented reduced mRNA expression in the enalapril-treated
group, when compared to the CIS group (Figure 2D). Preventive
treatment with enalapril reduced the intrinsic pathway of
apoptosis, as evidenced by the pro-apoptotic/anti-apoptotic ratio
shown by Bax/Bcl-2 mRNA expression (Figure 2D), as well
as the extrinsic pathway, as evidenced by TNFR-2 mRNA
expression (Figure 2D). This result suggests a reduced signaling
for apoptosis in mice treated with enalapril when compared to
mice treated with cisplatin alone.
Enhanced B1 Receptor mRNA Expression
Was Inhibited by Enalapril Treatment
Kinin B1 receptor is pro-inflammatory and its expression can
be induced by inflammation. Enalapril treatment prevents the
rise of B1 receptor mRNA expression (Figure 3A). Kinin B2
receptor also showed an increased expression after cisplatin
injection, but the difference between cisplatin-treated groups
was small and presented statistical difference only on the
fourth day (Figure 3B). The expression of ACE was lower
in ENAL + CIS group on the fourth day (Figure 3C).
The mRNA expression of other renin-angiotensin system
components, such as the AngII receptors, AT1R and AT2R,
was not strongly affected by preventive treatment with
enalapril (Figures 3D,E).
Enalapril Treatment Restores
Aminopeptidase P Activity
In the presence of a strong ACE inhibitor, such as enalapril,
the degradation of kinin peptides takes place by non-ACE
pathways (Kim et al., 2000). Aminopeptidase P (APP) has
a significant role in this degradation. Cisplatin reduces APP
activity in the kidney, diminishing kinin degradation and
increasing its inflammatory effects. On the other hand, enalapril
treatment restores APP activity in the kidney (Figure 4A). No
differences were found in serum APP activity after cisplatin
treatment (Figure 4B).
Enalaprilat Reduces Cisplatin-Induced B1R
and Pro-inflammatory Cytokines in Mouse
Epithelial Tubular Cells
In order to confirm the data found in animals, mouse
epithelial tubular cells MK55.K were incubated with cisplatin
and cisplatin+enalaprilat. Cisplatin increased B1R, NGAL, IL-
6, and TNF-α mRNA levels. Enalaprilat was able to abolish
the increase of these markers in mouse epithelial tubular cells
(Figures 5A–D).
FIGURE 1 | Effect of enalapril treatment in renal injury and function. Male mice were treated with cisplatin (CIS) or cisplatin plus enalapril (ENAL+CIS). (A) After 4 days
all cisplatin-treated groups had weight loss; Both serum creatinine and urea levels were reduced by enalapril treatment compared to CIS group. (B,C) Tubular injury
score analyzed by histology was smaller in ENAL+CIS group compared to CIS group (D–G). (D) Control (E) CIS (F) ENAL+CIS. Arrows indicates inflammatory
infiltration *p < 0.05, **p < 0.01, ***p < 0.001. compared to the control group. #p < 0.05; ###p <0.001. compared to the CIS group. Data presented as Mean ±
SEM n = 5–6.
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FIGURE 2 | Analysis of serum levels of cytokines and kidney expression of cytokines and apoptotic markers mRNA. (A–C) serum levels of pro-inflammatory
cytokines; (D) mRNA expression of cytokines and receptors involved in inflammation and mRNA expression ratio of pro- and anti-apoptotic proteins 4 days after
cisplatin treatment. *p < 0.05, **p < 0.01, ***p < 0.001. compared to the control group. #p < 0.05; ###p <0.001. compared to the CIS group. Data presented as
Mean ± SEM n = 5–6.
Enalaprilat Attenuates Cisplatin Toxicity in
Mouse Epithelial Tubular Cells and
Apstatin Blocks Its Effects
In this study, we treated mouse epithelial tubular cells MK55.K
with cisplatin, enalaprilat and apstatin (APP antagonist).
Cisplatin decreased cell viability, while enalaprilat was capable
of attenuating this decrease. Moreover, apstatin combined with
cisplatin and enalaprilat blocked enalaprilat benefits in mouse
epithelial tubular cells (Figure 6).
ACE Inhibition Blunts Increase of
Carboxypeptidase M Expression in vivo
and in vitro After Cisplatin Treatment
Carboxypeptidase M (CPM) facilitates B1R signaling (Zhang
et al., 2008, 2011, 2013a,b; Guimarães et al., 2019). The peak
of B1R expression after cisplatin injection is at 24 h; therefore,
we analyzed CPM expression in renal tissue 24 h after cisplatin
treatment. CIS increased CPM expression while ENAL+CIS
blunted this effect (Figure 7A). Mouse epithelial tubular cells
were treated with 50µM CIS, which increased B1R expression.
We observed also a trend to increased CPM expression, while
ENAL+CIS largely reduced its expression (Figure 7B).
DISCUSSION
The use of cisplatin in chemotherapy bears the risk of renal
injury. This is the main limitation for the use of this drug
in the treatment of some types of tumors. Preventing these
damaging effects may grant the use of higher doses of cisplatin
and improve its effect as a chemotherapeutic drug. Previous
studies have shown that the blockage of kinin B1 or B2 receptors
could protect the kidney from cisplatin-induced injury in mice
(Estrela et al., 2014a,b). These results open the possibility of
using B1 and B2 receptors antagonists for preventing renal injury
in patients undergoing cisplatin treatment. These receptors are
activated by kinins, which are mainly degraded by ACE. ACE
inhibitors reduce kinin degradation, are low-cost drugs and have
widespread use. They have few side effects and are approved for
human use. In the present work, we tested the effect of an ACE
inhibitor and found that enalapril treatment can also protect the
kidney from cisplatin-induced injury in mice. This conclusion
was drawn based on its ability to reduce cytokines expression,
reduce serum TNF-α, urea and creatinine levels, and to reduce
tubular injury and apoptosis signaling, as shown in mice treated
with cisplatin+ enalapril when compared to animals treated with
cisplatin alone.
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FIGURE 3 | (A–E) Renal mRNA expression of RAS and KKS receptors and ACE. The panels show the daily renal mRNA expression after cisplatin injection. B1R and
B2R = B1 and B2 kinin receptors; AT1R and AT2R = AT1 and AT2 angiotensin II receptors. *p < 0.05. Data presented as Mean ± SEM of fold changes; n = 5–6 per
group. CIS = Cisplatin; ENAL + CIS = Enalapril + Cisplatin.
FIGURE 4 | Renal and serum aminopeptidase P activity. Enalapril treatment prevents reduction in aminopeptidase P activity in kidney (A), no alterations were found in
aminopeptidase P activity in serum (B) 4 days after cisplatin injection. *p < 0.05 compared to the control group; #p < 0.05 compared to the CIS group. Data
presented as Mean ± SEM; n = 6 per group.
Since enalapril inhibits ACE and consequently leads to the
increase of kinin peptides’ half-life, we expected an increase in
deleterious effects of cisplatin in the kidney. Nonetheless, the
results indicated the opposite.
We analyzed both KKS and RAS components in an attempt
to understand the mechanisms involved in this protective effect.
Interestingly, although an ACE inhibitor drug was used, only
small changes were found in mRNA expression of the main
RAS components, such as AT1R, AT2R or ACE. One of these
changes was noted in ACE mRNA expression, which was lower
in ENAL+CIS group on the fourth day. On the other hand,
a strong effect was observed in KKS expression, as noted by
enalapril effect of blocking the increased expression of B1R
caused by cisplatin injection. Therefore, we confirmed, in vivo,
the phenomenon first observed in vitro by Ignjacev-Lazich et al.
(2005), i.e., the effect of ACE on the expression of B1R and B2R
genes. These authors showed that increasing ACE expression
in the vascular smooth muscle cell culture strongly induces the
upregulation of B1R and B2R expression by 22- and 11-fold,
respectively. This effect was inhibited by captopril, but not by
AT1R or AT2R antagonists (Ignjacev-Lazich et al., 2005). In the
present study, we showed that the inhibition of ACE activity
also downregulates the expression of both kinin receptors, with
a more pronounced effect on B1R expression. Given that kinin
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FIGURE 5 | Mouse epithelial tubular cells mRNA expression. The panels show mouse tubular cell mRNA expression of (A) B1R, (B) NGAL, (C) IL-6, and (D) TNF-α
after treatment with cisplatin and cisplatin + enalaprilat. Data presented as Mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001.
FIGURE 6 | Cell viability assay in mouse epithelial tubular cells. The panels
show cell viability assay in mouse tubular cells after treatment with cisplatin,
enalaprilat and apstatin. Data presented as Mean ± SEM; **p < 0.01, ***p <
0.001 compared to the control group. $$p < 0.01 $$$p < 0.001 compared to
the CIS+ENAL group.
peptides have a short half-life in the organism and that other
enzymes are able to degrade kinins, we speculate that the reduced
expression of kinin-receptor genes has a stronger inhibitory effect
in KKS, overcoming the possible increase in kinin concentration
or half-life. This data strongly suggests a mechanism for the
protective effect observed by enalapril treatment on cisplatin-
induced renal injury.
The blockage of both B2R and B1R is able to reduce cisplatin-
induced renal injury, as observed before (Estrela et al., 2014a,b).
The established knowledge that B2R is constitutively expressed
in most tissues including the kidney, and that B1R expression
is inducible by inflammation (Leeb-Lundberg et al., 2005) may
explain why only the B1R expression was strongly affected by
the preventive treatment with enalapril, while the B2R expression
presented only a smaller change. On the other hand, it is possible
that the reduction in B1R expression could be secondary to lower
inflammation caused by enalapril effects on other biological
targets, such as the decrease of AngII production. Moreover,
it has been shown that AT1R activation by AngII directly
increases B1R expression (Parekh et al., 2019). AngII is capable
of inducing kinin B1R via AT1R by releasing endothelin-1 and
activating the endothelin receptor A (Morand-Contant et al.,
2010). Moreover AngII can induce B1R through AT1R also by
activating NF-κB (Fernandes et al., 2006). B1R is capable of
increasing the production of iNOS and NADPH oxidase, which
leads to increased production of peroxynitrite and superoxide
anion enhancing oxidative stress and activating NF-κB and the
transcription of several inflammatory cytokines such as IL-1β
and TNF-α, iNOS, and B1R (Othman et al., 2019). Hence,
the inhibition of B1R signaling with enalapril can account for
the decrease production of these inflammatory cytokines in
our study.
Since upregulation of B2R by cisplatin is even more sustained
and synergistically contributes to renal damage (Estrela et al.,
2014b), the slight but significant reduction in B2R expression by
enalapril may also be of therapeutic relevance.
In the present study, while no strong changes in renal AT1R
expression were observed in enalapril-treated mice, part of the
reduction in renal inflammation and damage can also be due
to the expected reduction of AngII peptide, since enalapril is
a strong ACE inhibitor. AngII has been associated to kidney
inflammation in several models (Theuer et al., 2002; Altunoluk
et al., 2006; Benigni et al., 2011; Nagasawa et al., 2012; Kanda
et al., 2016; Ham et al., 2018; Panico et al., 2019), and the
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FIGURE 7 | Carboxypeptidase M mRNA expression in renal tissue and mouse epithelial tubular cells. The panels show CPM mRNA expression (A) in mice 24 h after
treatment with cisplatin or cisplatin plus enalapril and CPM mRNA expression (B) in mouse tubular cells after treatment with cisplatin or enalaprilat plus cisplatin. Data
presented as Mean ± SEM; **p < 0.01, ***p < 0.001.
FIGURE 8 | Schematic representation of cisplatin and enalapril effects on aminopeptidase P and B1R signaling in renal tubular cells. The scheme shows that cisplatin
(CIS) decreases APP activity, which leads to decreased kinin degradation that increases des-arg9-BK (DBK) availability and leads to increased inflammation and
apoptosis. It also shows that B1 receptor and CPM upregulation by cisplatin toxicity increases B1 receptor signaling. Additionally, it shows that enalapril+CIS
increases APP activity compared to CIS alone, increasing kinin degradation, which decreases des-arg9-BK (DBK) concentration, lowering inflammation and
apoptosis. On the other hand, enalapril also decreases B1 receptor and CPM expression reducing B1 receptor signaling.
reduction of its formation certainly has an anti-inflammatory
effect. Therefore, the changes in KKS components must be
considered mainly because they have been tested before alone
(Estrela et al., 2014a,b), with no inhibition of AngII formation,
and presented similar effects as those shown herein. The evidence
indicates the participation of KKS regulation in the mechanism
involved in renal protection against cisplatin side effects without
discarding the additional effect via AngII formation inhibition.
The measurement of kinin concentration in mice kidney
tissues is not feasible. However, it is possible to hypothesize
that kinin half-life or concentration in the kidney of mice
treated with both cisplatin and enalapril was increased. On the
other hand, the increased expression of aminopeptidase P (APP)
can be thoroughly discussed. APP is the second enzyme in
rank to degrade bradykinin, responsible for 30% of bradykinin
inactivation in the presence of active ACE (Prechel et al., 1995;
Fryer et al., 2008). This is the main non-ACE pathway of
kinin degradation and we speculate that the observed effect of
enalapril in restoring APP activity in the kidney must increase
kinin degradation by this non-ACE pathway, thus reducing
inflammation (Kim et al., 2000; Fryer et al., 2008). Moreover,
we confirmed the importance of APP in cultured cells, in which
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the combined treatment of cisplatin plus enalaprilat attenuated
cisplatin toxicity in renal epithelial tubular cells. When we
combined cisplatin, enalaprilat and apstatin, cell viability was
decreased, showing the importance of APP on enalaprilat
protective effects.
Carboxypeptidase M (CPM) is an ectoenzyme (Zhang
et al., 2013b), its catalytic domain hydrolyzes Lys or Arg
from C-terminal peptides (i.e., kallidin, bradykinin) which in
turn generates B1R agonists, des-arg10-kallidin or des-arg9-BK
(Skidgel et al., 1989). Moreover, CPM enhances B1R signaling
(Zhang et al., 2008, 2011, 2013a,b; Guimarães et al., 2019). In
our study we showed that B1R expression was diminished by
enalapril and enalaprilat treatment both inmice and cells and that
the generation of B1R agonists is also reduced due to a decrease
in CPM expression in vivo and in vitro.
Taken together, the results suggest that the protective effect
of enalapril on cisplatin-induced renal injury is not only due
to a reduction in AngII formation, but also by the modulation
of KKS components, mainly by blunting CPM expression, thus
reducing kinin B1 receptor agonism and its overexpression, and
preventing increases in kinin peptide concentrations through the
increased APP activity, acting locally in renal epithelial tubular
cells (Figure 8).
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